A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Clinical trial NCT04939142 · COMPLETED
Trial details
- NCT number
- NCT04939142
- Sponsor
- Antengene Corporation
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-12
- Primary completion
- 2024-08-26
- Enrollment
- 154
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.